Millimeter-scale positioning of a nerve-growth-factor source and biological activity in the brain
Open Access
- 13 April 1999
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 96 (8) , 4536-4539
- https://doi.org/10.1073/pnas.96.8.4536
Abstract
Toxicity prevents the systemic administration of many therapeutic proteins, and attempts at protein targeting via the circulatory system (i.e., “magic bullets”) have failed in all but a few special cases. Direct administration at the target site is a logical alternative, particularly in the central nervous system, but the limits of direct administration have not been defined clearly. Nerve growth factor (NGF) enhances survival of cholinergic neurons and, therefore, has generated considerable interest for the treatment of Alzheimer’s disease. We tested the effectiveness of local delivery by implanting small polymer pellets that slowly released NGF into the central nervous system of adult rats at controlled distances from a target site containing transplanted fetal cholinergic cells. NGF-releasing implants placed within 1–2 mm of the treatment site enhanced the biological function of cellular targets, whereas identical implants placed ≈3 mm from the target site of treatment produced no beneficial effect. Effective NGF therapy required millimeter-scale positioning of the NGF source, and efficacy correlated with the spatial distribution of NGF concentration in the tissue; this result suggests that NGF must be delivered within several millimeters of the target to be effective in treating Alzheimer’s disease. Because the human brain is divided into functional regions that are typically several centimeters in diameter and often irregular in shape, new methods for sculpting larger-scale drug fields are needed. We illustrate a concept, called pharmacotectonics, in which drug-delivery systems are arranged spatially in tissues to shape concentration fields for potent agents.Keywords
This publication has 28 references indexed in Scilit:
- Intrathecal Ciliary Neurotrophic Factor Delivery for Treatment of Amyotrophic Lateral Sclerosis (Phase I Trial)Neurosurgery, 1997
- Controlled Release of Proteins to Tissue Transplants for the Treatment of Neurodegenerative DisordersJournal of Pharmaceutical Sciences, 1996
- Nerve Growth Factor Delivery and Cell Aggregation Enhance Choline Acetyltransferase Activity after Neural TransplantationTissue Engineering, 1996
- Neuropathological Evidence of Graft Survival and Striatal Reinnervation after the Transplantation of Fetal Mesencephalic Tissue in a Patient with Parkinson's DiseaseNew England Journal of Medicine, 1995
- Implants of polymer‐encapsulated human NGF‐secreting cells in the nonhuman primate: Rescue and sprouting of degenerating cholinergic basal forebrain neuronsJournal of Comparative Neurology, 1994
- Transplantation of a Polymer-Encapsulated Cell Line Genetically Engineered to Release NGFExperimental Neurology, 1993
- Survival of Implanted Fetal Dopamine Cells and Neurologic Improvement 12 to 46 Months after Transplantation for Parkinson's DiseaseNew England Journal of Medicine, 1992
- Unilateral Transplantation of Human Fetal Mesencephalic Tissue into the Caudate Nucleus of Patients with Parkinson's DiseaseNew England Journal of Medicine, 1992
- Human nerve growth factor prevents degeneration of basal forebrain cholinergic neurons in primatesAnnals of Neurology, 1991
- Recombinant human nerve growth factor infusions prevent cholinergic neuronal degeneration in the adult primate brainAnnals of Neurology, 1991